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ABSTRACT
After its successful isolation from stools in the 1970s, Campylobacter jejuni has rapidly become the most
commonly recognised cause of bacterial gastroenteritis in man. Reported cases of human campylobac-
teriosis represent only a small fraction of the actual number. In industrialised countries, the incidence of
C. jejuni ⁄Campylobacter coli infections peaks during infancy, and again in young adults aged 15–44 years.
Acute self-limited gastrointestinal illness, characterised by diarrhoea, fever and abdominal cramps, is
the most common presentation of C. jejuni ⁄C. coli infection. The introduction of selective media has
made the diagnosis of Campylobacter enteritis a simple procedure. In general, Campylobacter enteritis is a
self-limiting disease which seldom requires antimicrobial therapy, although one in 1000 infections may
lead to the Guillain–Barre´ syndrome. In industrialised countries, most infections are acquired through
the handling and consumption of poultry meat. In developing countries, where the disease is confined to
young children, inadequately treated water and contact with farm animals are the most important risk
factors. Many infections are acquired during travel. Fluoroquinolone resistance has been reported in
C. jejuni since the late 1980s in Europe and Asia, and since 1995 in the USA. The use of fluoroquinolones
to treat animals used for food has accelerated this trend of resistance. In Australia, where
fluoroquinolones have not been licensed for use in food production animals, C. jejuni remains
susceptible to fluoroquinolones. The public health burden of Campylobacter spp. other than
C. jejuni ⁄C. coli remains unmeasured. Better diagnostic methods may reveal the true health burden of
these organisms.
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INTRODUCTION
Campylobacter spp. have been the focus of growing
attention for the past 30 years because of the
increasing frequency with which they have been
isolated from man, animals, food and water.
Although several Campylobacter spp. (C. jejuni,
C. coli, C. upsaliensis, C. lari, C. concisus, C. fetus
subsp. fetus, C. jejuni subsp. doylei, C. hyointesti-
nalis) and Arcobacter butzleri have been shown to
cause diarrhoea, C. jejuni is by far the most
frequent species isolated from man. C. jejuni is a
frequent cause of morbidity, in both industrial-
ised and developing countries, and represents a
considerable drain on economic and public health
resources. In the 1970s, collaboration between
medical doctors and their veterinary colleagues
led to the discovery of Campylobacter enteritis.
This review focuses on the historical perspectives
and the clinical, diagnostic and epidemiological
aspects of human campylobacteriosis.
HISTORICAL PERSPECTIVES
The beginnings
Although campylobacters were not recognised as
human pathogens until the 1970s, they have
probably caused illness in man for centuries. In
1886, Escherich published a series of articles in the
Mu¨nchener Medizinische Wochenschrift [1] in which
he described spiral bacteria in the colons of
children who had died of what he called ‘cholera
infantum’. Attempted culture on solid medium
was unsuccessful. Furthermore, he observed spi-
ral organisms microscopically in stool specimens
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from 35 of 72 infants suffering from enteric
disease but, despite the increased frequency,
thought the spiral bacteria played no aetiological
role [1]. Unfortunately, these articles, published
in German, remained unrecognised for many
decades until Kist [2] reported Escherich’s find-
ings at the Third International Campylobacter
Workshop held in Ottawa in 1985.
The veterinary era
Found frequently in animals, particularly in
bovines and ovines, Campylobacter has been
known for more than 40 years as a cause of
veterinary disease. In 1909, two veterinary sur-
geons, McFadyean and Stockman [3], surveyed
epizootic abortion in ewes and reported an
unknown bacterium that was frequently isolated
from aborted foetuses and which resembled a
vibrio. In 1919, Smith investigated infectious
abortions of bovines in the USA and isolated (in
addition to the ‘Bacillus of Bang’) a bacterium that
was described as a spirillum [4]. Finishing the
study, Smith became acquainted with the work of
McFadyean and Stockman, and assumed that
they had been studying the same bacteria. He
confirmed this, together with Taylor, and pro-
posed the name ‘Vibrio fetus’ [5]. In 1949, Stegenga
and Terpstra demonstrated the pathogenic role of
V. fetus venerealis in enzootic sterility in cows [6].
In 1959, Florent was able to distinguish two types
of V. fetus by their biochemical and pathogenic
characteristics, namely V. fetus venerealis and
V. fetus intestinalis [7]. In 1931, Jones et al. [8]
attributed winter dysentery in calves to infection
with a ‘vibrio’ that they called Vibrio jejuni, and
Doyle described a similar organism associated
with swine dysentery in 1944 [9].
First human infections
In 1947, Vinzent et al. [10] isolated V. fetus from
the blood of three pregnant women admitted to
hospital because of fever of unknown origin. The
illness lasted about 4 weeks, and two of the three
women aborted. On examination, large necrotic
and inflammatory areas were found on the
placenta. However, even before this report, an
event took place in Illinois in May 1938 that is
now regarded as the first well-documented
instance of human Campylobacter infection [11].
This involved a milk-borne outbreak of diarrhoea
that affected 355 inmates of two adjacent state
institutions. Faecal cultures from 73 victims tested
were negative, although microscopy was positive
in 31 cases, but organisms resembling ‘V. jejuni’
were grown in broth cultures of the blood of 13
victims.
In 1957, King [12,13] described a vibrio with
several features in common with the agents
described by Vinzent, but with different bio-
chemical and antigenic characteristics. King
termed this organism ‘related vibrio’ but, until
1972, only 12 cases of ‘related vibrio’ infections
were reported in the literature, involving seven
infants, two children and three adults [12,14–17].
The reason for this paucity of reports was that the
selective culture techniques necessary for the
isolation of this organism, later renamed by
Sebald and Ve´ron [18] as Campylobacter, from
faeces had not been developed at that time.
Consequently, the infection could be diagnosed
only from the blood of bacteraemic patients.
However, King believed that the infection was
not as rare as these few reports suggested, and
emphasised the need to devise a method for
culturing the organisms from faeces. Unfortu-
nately, such a method was not developed in her
lifetime, but her vision and diligence paved the
way.
The breakthrough
The crucial step—the isolation of Campylobacter
from faeces—was accomplished in 1968 by
Dekeyser at the National Institute for Veterinary
Research, Brussels Belgium, in conjunction with
Butzler and his team at the St Peter University
Hospital, and was published in 1972 [19]. A
20-year-old female was admitted on 18 July 1968
to the St Peter University Hospital in Brussels
with severe diarrhoea and fever (40C). There was
no underlying pathology. A ‘related vibrio’
(C. jejuni) was isolated from blood and, after use
of a special filtration technique, from the faeces.
This technique consisted of differential filtration
of faecal suspensions through 0.65-lm filters,
which allowed Campylobacter organisms to pass
through. The filtrate was then inoculated on to a
selective medium. No other enteric pathogens
were isolated from the stools of this patient. This
first faecal culture demonstrated intestinal infec-
tion as the origin of the bacteraemia. This clinical
case was the starting point of a collaboration
Butzler Campylobacter, from obscurity to celebrity 869
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 868–876
between Butzler and Dekeyser, which included a
search for campylobacters in the stools of healthy
individuals and patients with diarrhoea, a search
for specific serum antibodies in these groups, the
collection of clinical data, and the elaboration of a
therapeutic scheme. C. jejuni ⁄C. coli were isolated
from 5.3% of 3800 children with diarrhoea, but
from only 1.6% of 7200 individuals without
diarrhoea [20]. Specific complement-fixing anti-
bodies to the strain of C. jejuni isolated from stools
were demonstrated in children with diarrhoea
[21]. Of most importance was the finding of a high
susceptibility of C. jejuni to erythromycin [21,22].
Once the sensitivity of C. jejuni to erythromycin
was known, this antibiotic was used as a thera-
peutic test [21]. The cessation of diarrhoea in
combination with the disappearance of C. jejuni
from stools was an argument in favour of C. jejuni
being the cause, since erythromycin had no effect
on ordinary intestinal pathogens. In all treated
cases, erythromycin caused the symptoms to
disappear rapidly.
Subsequently, the invasive ability of C. jejuni
was demonstrated in poultry [21]. Antigenic
typing of the C. jejuni isolates was performed
by agglutination and complement fixation tests
with antisera raised from reference strains of
C. jejuni and C. coli. A close antigenic relation-
ship, and even identity, was shown between
isolates from man and those from poultry, sheep
and pigs [21]. In 1973, Butzler [23] reported the
first cases of Campylobacter enteritis in the tropics
(in Zaire, now the Democratic Republic of
Congo). In 1977, Skirrow [24] confirmed the
findings of the Belgian team and described a
simpler technique for culturing C. jejuni and
C. coli from stool specimens, which allowed
widespread isolation of these organisms. The
later development of selective media, obviating
the need to filter suspensions, brought the
isolation of Campylobacter into the realm of
routine microbiology [24–30]. Reports from
industrialised countries, including European
countries [19–21,24,30–33], Canada [34] and the
USA [35], and from developing countries, inclu-
ding Zaire [23] and Rwanda [36], have shown
that Campylobacter enteritis occurs worldwide. In
1979, the first full account of Campylobacter
enteritis in man was published [37], and in the
1980s Penner and Hennessy [38] and Lior et al.
[39] described serotyping techniques that, aided
by biotyping, phage typing and genotyping, still
form the basis of strain typing. It was not until
the mid-1980s that C. jejuni was recognised as
the most frequent cause of bacterial enterocolitis
in man.
CLINICAL MANIFESTATIONS
In the industrialised world, acute self-limited
gastrointestinal illness, characterised by diar-
rhoea, fever and abdominal cramps, is the most
common presentation of C. jejuni infection, but
symptoms and signs are not so distinctive that
the physician can differentiate this infection
from illness caused by other organisms
[21,24,31–35,40]. The incubation period is com-
monly 2–5 days, but estimates have extended
up to 10 days. In c. 50% of patients, diarrhoea is
preceded by a febrile period with malaise,
myalgia, abdominal pain and fever of c. 40C;
fresh blood may appear in the stools by the
third day. Faecal samples show an inflammatory
exudate with leukocytes on microscopic exam-
ination; moreover, it is usually possible to
recognise numerous Campylobacter organisms
from their characteristic morphology. Vomiting
is rare. The diarrhoea continues for c. 2–3 days,
but abdominal pain and discomfort may persist
after the diarrhoea has stopped. In a significant
proportion of patients, the stools contain fresh
blood, pus or mucus, which suggests that
colorectal inflammation is not uncommon in
Campylobacter infection. Sigmoidoscopy usually
reveals abnormalities ranging from mucosal
oedema and hyperaemia, either with or without
petechial haemorrhage, to mucosal friability.
Severe abdominal pain may mimic acute peri-
tonitis. Occasionally, these patients, especially
teenagers or young adults, develop peritonitis
from acute appendicitis, but in most patients
there is inflammation of some part of the ileum
and jejunum with mesenteric adenitis [37,40–42].
Local complications such as cholecystitis, pan-
creatitis and peritonitis occur rarely [42].
Recently, immunoproliferative small intestinal
disease has been associated with C. jejuni [43].
Bacteraemia is detected in < 1% of patients with
Campylobacter enteritis, and occurs most often in
patients whose immune system is severely
compromised [40–42,44]. Some patients develop
erythema nodosum or reactive arthritis. Extra-
intestinal infections, including meningitis [45],
osteomyelitis [46] and neonatal sepsis, are rare.
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It has been recognised that the paralytic condi-
tion, Guillain–Barre´ syndrome (GBS), is the most
serious complication of Campylobacter infection
[47–52], with an incidence of 1 ⁄ 1000 infections
[41,42,47–52]. C. jejuni is the most frequently
observed antecedent infection in cases of GBS. In
general, one in three GBS patients has suffered
from a preceding infection with C. jejuni. Symp-
toms of GBS usually occur 1–3 weeks after the
onset of Campylobacter enteritis. GBS cases associ-
ated with Campylobacter infection are usually more
severe and can require intensive hospital treat-
ment, with possible long-term disability. Molecu-
lar mimicry has been proposed as an attractive
concept to explain the pathogenesis of GBS
[49–52]. Starting with food-borne Campylobacter
diarrhoea, antibodies and ⁄ or T-cells are induced
by the infection and are directed initially against
Campylobacter, leading to eradication of the organ-
ism. However, because of the strong resemblance
between the microbial antigens and the self-anti-
gens, in this example the peripheral nerve cells,
the tissue is destroyed, leading to GBS [49–52].
MICROBIOLOGY
Campylobacter and Arcobacter are now included in
the family Campylobacteriaceae [53–56]. When
the diagnosis of infection is based exclusively
upon culture on selective media, it appears that
> 95% of Campylobacter infections are caused by
C. jejuni or C. coli. However, with refinements in
isolation and identification methods, other related
species, such as C. upsaliensis [57,58], C. lari [59],
C. fetus subsp. fetus [60,61], C. jejuni subsp. doylei
[61], C. concisus [61,62], A. butzleri [63–68] and
Arcobacter skirrowii [69], have been isolated from
human patients with diarrhoea.
Campylobacter spp. are small, curved or spiral-
shaped Gram-negative bacilli that exhibit rapid
darting and spinning motions. In a clinical con-
text, the main role of the laboratory is to detect
campylobacters in the faeces of patients with
diarrhoea. For same-day deliveries to the laborat-
ory, faeces can be transported in conventional
containers, but if delay is anticipated, faeces
should be put in transport medium, such as
Cary–Blair medium, and kept cool [37,40–
42,60,61,70]. Transport medium should also be
used for rectal swabs. Modern blood culture
systems are efficient at detecting Campylobacter
bacteraemia, and blood cultures should be taken
if the clinical features and immunocompetence of
the patient indicate campylobacteriosis [70].
Campylobacter enteritis can be diagnosed read-
ily by direct microscopic examination of fresh
liquid faeces, either with Gram’s stain (counter-
stain with carbol fuchsin) or a phase-contrast
optical system. Campylobacter spp. can be seen
and distinguished from other organisms by
virtue of their spiral morphology and extremely
rapid darting and spinning motions. Commer-
cial kits are available for the direct detection of
C. jejuni and C. coli antigens in faeces, e.g., by
latex agglutination [71,72]. PCR-based identifi-
cation methods can detect several Campylobacter
spp., including some uncommon species that
are difficult to culture [73]. An advantage of
PCR methods over culture is the ability to
achieve same-day detection and speciation of
the organism, but these methods are expensive,
are labour-intensive, and do not provide an
isolate for typing or sensitivity testing.
C. jejuni and C. coli can be isolated easily from
faeces by primary plating on selective media and
incubation for 48–72 h at 42C in a microaerobic
atmosphere. A variety of selective media (blood-
based, blood-free charcoal-based) are available
[24–30]. These contain antibiotics that suppress
the normal bacterial enteric flora. However, the
antibiotic-containing Campylobacter selective med-
ia and the elevated incubation temperature (42C)
may also inhibit the growth of some of the
Campylobacter spp. encountered less commonly.
If a Campylobacter sp. other than C. jejuni is
suspected, stool filtration and culture on a non-
selective medium, with incubation at 37C and
42C, should also be used [61–70].
The minimal standards for identifying Cam-
pylobacter spp. after primary isolation are colony
morphology, Gram’s stain, motility and an
oxidase test. The hippurate hydrolysis test
differentiates most C. jejuni strains from other
Campylobacter spp. [37,70]. For organisms other
than C. jejuni and C. coli, including atypical
C. jejuni strains, additional biochemical tests are
required. Several typing methods, namely sero-
typing [38,39,74,75], phage-typing [76], pulsed-
field gel electrophoresis [77] and genotyping
[78], can be used to characterise the strains
further. Serology is indicated for certain culture-
negative cases of suspected C. jejuni infection
involving reactive arthritis, erythema nodosum
and GBS [79,80].
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TREATMENT
In general, Campylobacter enteritis has a very good
prognosis, and the isolation of these organisms
from stools does not warrant chemotherapy
[21,24,35,37]. In the absence of chemotherapy,
faeces remain positive for c. 2–7 weeks after the
illness. Antibiotic therapy is indicated for patients
with Campylobacter infection who are acutely ill
with enteritis, have persistent fever, bloody diar-
rhoea, have more than eight bowel move-
ments ⁄day or significant volume loss, or have a
> 7-day history of diarrhoea. HIV-positive or
immunocompromised individuals should receive
antibiotic treatment [40–42]. When antimicrobial
therapy is indicated, erythromycin is the drug of
choice, given its efficacy, low toxicity and low cost
[21,24,35,37,40–42,81,82].
Fluoroquinolones such as ciprofloxacin have
been used commonly for the treatment of infec-
tions caused by Campylobacter. However, since the
late 1980s, fluoroquinolone resistance has been
reported from Europe [83,84], Asia [85], and Latin
America [86]; since 1995, it has also been reported
from the USA [87–90]. The prevalence of fluoro-
quinolone-resistant C. jejuni in the USA was 0% in
1990, increasing to 13% in 1997, and to 18% in
1999, following the approval of fluoroquinolones
for use in poultry farming in 1995 [87–90].
In contrast, in Australia, where fluoroquino-
lones are not used in poultry farming, human
Campylobacter isolates remain susceptible to
fluoroquinolones [91]. In the USA, eating poul-
try outside the home and foreign travel have
both been identified as risk factors for infections
with fluoroquinolone-resistant Campylobacter
spp. [87–90,92–94]. In industrialised countries,
dehydration caused by C. jejuni is infrequent,
but fluid and electrolyte replacement are some-
times necessary for infected infants. However,
the best treatment for C. jejuni infections in
developing countries could well prove to be
different. Factors such as low socio-economic
status and malnutrition may determine the
severity of infection with C. jejuni and its great
prevalence in very young children. Vomiting
and watery diarrhoea are frequent, and oral
rehydration is sometimes required in children.
Antibiotics should be reserved for severe cases.
It is certain that education and better hygiene
have far greater roles in reducing infections
than do antibiotics [82].
EPIDEMIOLOGY
Campylobacter enteritis is the most frequent form
of acute bacterial diarrhoea in industrialised
countries, where it affects people of all ages but
with a distinctive bimodal distribution, affecting
particularly children aged < 4 years and young
adults aged 15–44 years [95]. Individuals with
AIDS are at higher risk of acquiring Campylobacter
spp. and have a greater risk of invasive disease.
The infection is seasonal in temperate climates.
About twice as many infections occur in summer
as in winter.
Campylobacteriosis is a zoonosis [21,24,37,40–
42,60,96]. The reservoir of infection comprises
wild and domestic animals, particularly birds.
Chickens constitute by far the largest potential
source of human infection. Campylobacteriosis is
mainly a food-borne infection in which foods of
animal origin, particularly poultry, play an
important role [96–100]. Any raw meat bred for
consumption may be contaminated with Campy-
lobacter organisms. Almost all parts of poultry
carcasses, whether fresh, chilled or frozen, are
frequently contaminated with C. jejuni. Raw or
undercooked beef, hamburgers, sausages and
clams have also been implicated in outbreaks of
Campylobacter enteritis, but, generally, food-borne
outbreaks, as opposed to sporadic food-borne
infections, are uncommon. Epidemiological inves-
tigations have demonstrated a significant correla-
tion between the handling and consumption of
poultry meat and the occurrence of Campylobacter
enteritis.
In June 1999, the dioxin crisis, caused by
dioxin-contaminated food components, resulted
in the withdrawal of chicken and eggs from the
market in Belgium. Through the sentinel surveil-
lance system, a corresponding decrease in Cam-
pylobacter infections during June 1999 was noticed
[101]. Barbecues and similar activities appear to
present special hazards for infection, as they
permit easy transfer of bacteria from raw meat
to hands and other foods, and from these to the
mouth. Raw or inadequately heat-treated milk
and inadequately treated water have been incrim-
inated as sources of massive outbreaks of infec-
tion [102].
Direct transmission is mainly occupational
(farmers, butchers, abattoir workers, poultry proc-
essors), but pets can bring infection into ordinary
homes. Inter-human transmission has been
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described infrequently in young children. Perinatal
transmission, from a patient who is not necessarily
symptomatic, may occur following exposure
in utero, during passage through the birth canal,
or during the first days of life. Many cases of
campylobacteriosis are associated with foreign
travel, accounting for 3–50% or more of all cases,
and usually result from the consumption of con-
taminated food or water in the countries visited. In
developing countries where campylobacters are
hyper-endemic, the disease is confined to young
children who, through repeated exposure to infec-
tion, develop immunity early in life [103–105]. In
these countries, Campylobacter plays an important
role, and its effects are particularly acute during
weaning. Consequently, campylobacteriosis con-
tributes significantly to malnutrition in infants,
who represent an at-risk group. In developing
countries, exposure in the household to the faeces
of live chickens infected with C. jejuni is the
predominant risk factor for childhood diarrhoea.
Exposure to inadequately treated water is also
assumed to be an important risk factor.
A lack of national surveillance data prevents
the public health impact and the burden of
Campylobacter infections in developing countries
from being assessed. The recent incorporation of
Campylobacter in the WHO Salmonella surveillance
network (WHO SalmSurvNet) may allow the
development of a more accurate picture regarding
the public health impact and the burden of
campylobacteriosis in developing countries. The
public health burden of Campylobacter spp. other
than C. jejuni ⁄C. coli remains unknown in both
industrialised and developing countries.
PREVENTION
As the major source of human campylobacteriosis
in the industrialised world is poultry, prevention
should aim at reducing infection at all stages of
poultry production. It is difficult to control Cam-
pylobacter during poultry processing because of
the high incidence of this pathogen in poultry
flocks and the high levels in chicken intestines.
The strategies that have been successful for
controlling Salmonella infection in poultry are
generally ineffective against campylobacters
[106]. More information is needed about the
effectiveness of biosecurity measures for poultry
farms, and about the impact of these measures on
human campylobacteriosis. Campylobacter is rel-
atively sensitive to low-dose radiation treatment
and could be eliminated readily from poultry
meat products by this means, but there is still
considerable resistance among consumers to this
method of disinfection. Appropriate precautions
in the handling and preparation of foods of
animal origin will reduce cross-contamination.
Raw meat and poultry should be cooked ade-
quately. Hands should be washed thoroughly
with soap after handling raw foods of animal
origin and before touching anything else. Chop-
ping boards used for raw meats should not be
used for preparing other foods. Chopping boards
and utensils should be cleaned with soap and hot
water after preparation of raw food of animal
origin [107,108].
Campylobacter is an important cause of travel-
lers’ diarrhoea. A World Health Organization fact
sheet on avoiding travellers’ diarrhoea is avail-
able. The Copenhagen consultation [109] recom-
mends that the World Health Organization
should educate travellers on the risks involved
in travelling, give advice on the avoidance of
Campylobacter infections, and publish relevant
data concerning antibiotic resistance in different
countries. Prevention depends also on the purifi-
cation of water supplies and the heat treatment of
milk sold for consumption. In developing coun-
tries, the keeping of chickens outside the home
and the prevention of contact with their faeces
reduces transmission of C. jejuni substantially
[110]. Breast-fed infants are less likely to develop
Campylobacter-associated diarrhoea than their
non-breast-fed counterparts [111]. Campylobacter
vaccines have shown promise in animal models
[112,113]. The recent determination of the genome
sequence of C. jejuni [114] will facilitate the
development of a safe and effective Campylobacter
vaccine for possible application in the prevention
of travellers’ diarrhoea.
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